Wund(er)heilung mit Amnion – DGFG erhält deutschen Wundpreis 2021
Ausschreibung DGNI-Pflege- und Therapiepreis 2022
Ausschreibung: Otsuka Team Award Psychiatry+ 2021
BGW-Gesundheitspreis 2022: Gute Praxis aus der Altenpflege gesucht!
Aktionsbündnis Patientensicherheit vergibt Deutschen Preis für Patientensicherheit 2021 an herausragende…
8.-10. September 2021: Weimar Sepsis Update 2021 – Beyond the…
13.09. – 18.09.2021: Viszeralmedizin 2021
24.06. – 26.06.2021: 27. Jahrestagung der Deutschen Gesellschaft für Radioonkologie
17.06. – 19.06.2021: 47. Jahrestagung der Gesellschaft für Neonatologie und…
16. bis 18. Juni 2021: Deutscher Kongress für Psychosomatische Medizin…
New meta-analysis finds cannabis may be linked to development of opioid use disorders
Northampton, UK (July 15, 2021) — The idea that cannabis is a ‘gateway drug’ to more harmful substances such as opioids is controversial, yet has substantially impacted drug policy, education and how we conceptualize substance use. A new systematic review and meta-analysis has found that people who use cannabis are disproportionately more likely to initiate opioid use and engage in problematic patterns of use than people who do not use cannabis. But the quality of the evidence for this finding is low.
One surprising discovery in this meta-analysis, led by researchers at the University of Sydney’s Matilda Centre for Research in Mental Health and Substance Use and published by the journal Addiction, was that there aren’t many good studies on the gateway drug theory. Despite the frequency with which the topic of gateway drugs is discussed, only six studies were of high enough quality to include. A synthesis of the evidence from those six studies demonstrated that people who use cannabis are more than twice as likely to initiate opioid use and develop problematic patterns of use than people who don’t use cannabis.
But the quality of the evidence in those studies is low and must be interpreted with caution. All six studies had a moderate risk of bias and overlooked important confounding variables such as cannabis use frequency and affiliation with cannabis or opioid-using peers. It is unclear whether these unmeasured variables would have had a strong enough impact to explain away the cannabis-opioid use relationship.
It is therefore not possible, on the existing evidence, to state conclusively that there is a causal relationship between cannabis and subsequent opioid use, but it is likely that there is at least a partial causal relationship.
The six studies provided data from the United States, Australia and New Zealand between 1977 and 2017, with a total sample of 102,461 participants.
Peer reviewed: Yes
Type of study: Review
Subject of study: People
Funding: Government/research council, charity/NGO, and university
This paper is free to download for one month from the Wiley Online Library: https://onlinelibrary.wiley.com/doi/abs/10.1111/add.15581 or by contacting Jean O’Reilly, Editorial Manager, Addiction, firstname.lastname@example.org.
A podcast with Mr Jack Wilson is available at Addiction Audio: https://shows.acast.com/addiction-audio
Full citation for article: Wilson J, Mills K, Freeman TP, Sunderland M, Visontay R, and Marel C. (2021) Weeding out the truth: a systematic review and meta-analysis on the transition from cannabis use to opioid use and opioid use disorders, abuse or dependence. Addiction 116: doi:10.1111/add.15581
Funding: Project supported by the Australian National Health and Medical Research Council (NHMRC), the University of Sydney’s Matilda Centre for Research in Mental Health and Substance Use, the University of Sydney, and the Society for the Study of Addiction.
Addiction (http://www.addictionjournal.org) is a monthly international scientific journal publishing peer-reviewed research reports on alcohol, substances, tobacco, and gambling as well as editorials and other debate pieces. Owned by the Society for the Study of Addiction, it has been in continuous publication since 1884.
Society for the Study of Addiction, 15.07.2021 (tB).Schlagwörter: Cannabinoide, Schmerzmedizin, Suchtmedizin